- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Enzene Biosciences Romiplostim gets DCGI marketing authorization
Romiplostim, a therapeutic fusion protein, acts as a thrombopoieses stimulating factor, thereby restoring platelet levels and ameliorating the disease.
New Delhi: Enzene Biosciences Ltd. "Enzene" announced a successful Marketing Authorization (MA) from the Drug Controller General of India (DCGI) for its second biosimilar drug "Romiplostim", indicated for the treatment of chronic Immune Thrombocytopenic Purpura (ITP) in adults.
In doing so, Enzene becomes the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg).
ITP is a rare haematological disorder (prevalently autoimmune) with a primary clinical presentation of aberrantly low platelet levels, and symptoms including an increased bruising and bleeding tendency.
Romiplostim, a therapeutic fusion protein, acts as a thrombopoiesis stimulating factor, thereby restoring platelet levels and ameliorating the disease. As such, it remains one of the most reliable long-term treatment options for ITP patients.
According to Dr. Himanshu Gadgil, Enzene's Whole Time Director, "With the approval of Enzene's Romiplostim drug in India, we are happy to bring this life-saving therapy to ITP patients. Enzene is now actively developing strategic partnerships to further expand global access to this therapy."
Read also: JnJ eyes CDSCO nod for single shot COVID vaccine trials in 12-17 year olds
Fresh off the launch of Enzene's first biosimilar Teriparatide (indicated for the treatment of osteoporosis) earlier this year, Sandeep Singh, Managing Director, Alkem Laboratories Ltd., said, "Alkem's long-standing primary mission to provide widespread affordable access to medicines in the Indian pharmaceutical market has received a huge boost today with our subsidiary Enzene's second biosimilar launch within the year. Alkem has built an exceptional strength in the clinical research and testing group and we remain dedicated as ever, to bringing many such therapies in the near future."
Read also: Bharat Biotech study on Covaxin, nasal COVID jab cocktail gets DCGI nod: Report
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751